QurAlis ALS Drug Shows 50% Reduction in Disease Progression as FDA Clears U.S. Clinical Trial

0
15
Dr. Kasper Roet

CAMBRIDGE, Mass.–QurAlis Corporation has received clearance from the U.S. Food and Drug Administration to advance its experimental amyotrophic lateral sclerosis (ALS) treatment, QRL-201, into a pivotal U.S. clinical trial after reporting promising results from an earlier study.

The company announced that final results from the dose-range finding phase of its Phase 1/2 ANQUR clinical trial showed that patients receiving the higher dose of QRL-201 experienced a 50% reduction in functional decline compared with those receiving a placebo, as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R).

The FDA’s clearance of the company’s Investigational New Drug application allows QurAlis to proceed with plans for its pivotal CONQUR trial, which is expected to begin during the first half of 2027.

ALS, also known as Lou Gehrig’s disease, is a progressive neurodegenerative disorder that damages nerve cells responsible for controlling voluntary muscle movement. The disease eventually affects patients’ ability to walk, speak, swallow and breathe. There is currently no cure.

QRL-201 is an investigational antisense oligonucleotide therapy designed to restore production of STATHMIN-2 (STMN2), a protein essential for maintaining nerve cell function, repairing nerve damage and supporting connections between nerves and muscles.

STMN2 levels are significantly reduced in most patients with ALS, largely because of abnormalities involving the protein TDP-43. By restoring STMN2 expression, QurAlis hopes to slow the progression of the disease.

“We are delighted to receive FDA clearance of the IND for QRL-201, our lead program in ALS, marking an important milestone for QurAlis and highlighting the Agency’s support for rare diseases like ALS,” said Kasper Roet, Ph.D., CEO and co-founder of QurAlis. “We are equally encouraged by the final results from the ANQUR clinical trial evaluating QRL-201 in ALS patients, which show a remarkable slowing of the disease, consistent and significant effects across neurofilaments, and clear evidence of target engagement in sporadic ALS. QurAlis looks forward to progressing the pivotal CONQUR clinical trial of QRL-201 in ALS to deliver an innovative precision medicine solution capable of modifying disease progression and enhancing clinical outcomes for individuals living with sporadic ALS.”

The completed dose-range finding phase of ANQUR evaluated 52 patients with sporadic ALS who received either 10 milligrams or 3 milligrams of QRL-201 or a placebo.

At Day 253, both treatment groups demonstrated slower functional decline, with the 10-milligram group achieving a statistically significant 50% reduction in ALSFRS-R progression compared with placebo.

Researchers also observed reductions in biomarkers associated with nerve cell damage.

Patients receiving the 3-milligram dose experienced a 46% reduction from baseline in cerebrospinal fluid phosphorylated neurofilament heavy chain (pNfH) levels at Day 197. The reduction was statistically significant.

The same treatment group demonstrated an 18% reduction from baseline in plasma neurofilament light chain (NfL) at Day 337, while patients receiving the 10-milligram dose showed a 36% reduction at Day 421.

Neurofilament proteins are released when nerve cells are damaged, making them important biomarkers for evaluating neurodegeneration and potential treatment effects in ALS.

QurAlis reported that QRL-201 was generally well tolerated throughout the study, with most adverse events classified as mild or moderate. No serious adverse events were reported during the dose-range finding phase.

Dr. Merit E. Cudkowicz, Director of the Sean M. Healey & AMG Center for ALS, Executive Director of the Mass General Brigham Neuroscience Institute and Julieanne Dorn Professor of Neurology at Harvard Medical School, said the findings support further investigation of the treatment.

“ALS is a serious neurodegenerative disease that represents a considerable unmet medical need. STATHMIN-2 is one of the most significantly downregulated proteins in sporadic ALS. Recent scientific evidence has shown that STATHMIN-2 levels can be restored by an ASO, a technology with known effectiveness in ALS. The findings from the ANQUR clinical trial are promising and justify additional clinical research into QRL-201 as a potential treatment option for individuals with sporadic ALS,” said Cudkowicz, who also serves on QurAlis’ Clinical Advisory Board.

The ANQUR study has now entered its open-label extension phase, with 41 patients receiving ongoing treatment with the 3-milligram dose of QRL-201 across clinical sites in Canada, the United Kingdom and the European Union.

The earlier multiple ascending dose phase enrolled 17 patients, while the subsequent dose-range finding phase included 52 participants.

QurAlis plans to provide additional details about the pivotal CONQUR trial in early 2027.

The upcoming study will represent a significant next step in determining whether restoring STMN2 expression can produce sustained clinical benefits for patients with ALS and potentially alter the course of the disease.

Leave A Reply

Please enter your comment!
Please enter your name here